News | March 23, 2026
Zydus launches affordable Semaglutide in India after patent expiry
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Under the PMBJP, till 30.06.2022, 8742 PMBJKs have been opened across the country including Government Hospitals and Government premises.
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
Subscribe To Our Newsletter & Stay Updated
